Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Core Viewpoint - Beam Therapeutics Inc. is set to announce its fourth quarter and full year 2025 financial results along with a new liver-targeted genetic disease program on February 24, 2026 [1]. Company Overview - Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines through base editing [3]. - The company has established a fully integrated platform that includes gene editing, delivery, and internal manufacturing capabilities [3]. - Beam's proprietary base editing technology allows for precise and efficient single base changes in targeted genomic sequences without causing double-stranded breaks in DNA [3]. - The company aims to provide lifelong cures for patients suffering from serious diseases and is committed to cutting-edge science and its workforce [3]. Investor Information - The live webcast for the financial results announcement will be available on the investor section of the company's website and will be archived for 60 days [2].